Pain drug in pipeline as researchers unwind marine snail puzzle

School of Biomedical Sciences researcher Dr Richard Clark said marine snail venom was a well-known and promising source of new pain drugs, but substantial hurdles had restrained progress.

"Translating the venom's toxins into a viable drug has proved difficult," Dr Clark said.

"But now we've been able to identify a core component of one of these conotoxins (toxins from cone snail venom) during laboratory tests.

"We think this will make it much easier to translate the active ingredient into a useful drug."

Dr Clark said a sea snail used its venom to immobilise prey and protect itself.

"The venom's analgesic properties have been well researched," he said.

"In this study, we've been able to shrink a particular conotoxin to its minimum necessary components for the pain relief properties to continue to work.

"Using a laboratory rat model, we used the modified conotoxin to successfully treat pain generated in the colon, similar to that experienced by humans with irritable bowel syndrome.

"Although the conotoxin has been modified, its pain relief properties remained as effective as the full-size model.

"Simplifying the conotoxin will make a drug much faster and cheaper to develop."

Dr Clark said further research was under way to improve the modified conotoxin's stability and to test its ability to treat other types of pain.

The research, published in Angewandte Chemie International Edition, was undertaken in collaboration with Professor David Craik at UQ's Institute for Molecular Bioscience, Professor David Adams at the Royal Melbourne Institute of Technology and Associate Professor Stuart Brierley at the University of Adelaide.